nach oben

Erschienen in:

07.06.2016 | Original Article

The utility of PET/CT with ⁶⁸Ga-DOTATOC in sarcoidosis: comparison with ⁶⁷Ga-scintigraphy

verfasst von: Tomomi Nobashi, Yuji Nakamoto, Takeshi Kubo, Takayoshi Ishimori, Tomohiro Handa, Kiminobu Tanizawa, Kohei Sano, Michiaki Mishima, Kaori Togashi

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study was designed to compare the clinical efficacy of ⁶⁸Ga-DOTA-Tyr-octreotide (DOTATOC)-positron emission tomography (PET)/computed tomography (CT) with that of conventional ⁶⁷Ga-scintigraphy (GS), and to correlate quantitative parameters on DOTATOC-PET/CT with clinical data, in patients with sarcoidosis.

Methods

Twenty patients who were histologically and/or clinically diagnosed with sarcoidosis and underwent both DOTATOC-PET/CT and GS were analyzed in this study. The numbers of patients with positive findings for each organ were determined. The total numbers of involved nodal areas in the chest, as determined by DOTATOC-PET and gallium single-photon emission tomography (Ga-SPECT), were compared. The correlations between quantitative parameters on PET and clinical laboratory data were evaluated.

Results

DOTATOC-PET/CT was positive in 19 patients, being negative in only one patient with chronic inactive sarcoidosis, whereas GS was positive in 17 patients. DOTATOC-PET/CT visualized more lesions in lymph nodes, uvea, and muscles than did Ga-scintigraphy and identified more involved areas than did GS-SPECT (p < 0.0001). Whole-body active lesion volume showed a significant, but moderate correlation with angiotensin-converting enzyme level (ρ = 0.64, p = 0.0044).

Conclusions

PET/CT with DOTATOC may be superior to conventional GS in detecting sarcoidosis lesions, especially in lymph nodes, uvea, and muscles. Volumetric parameters in DOTATOC-PET/CT may be helpful in estimating the activity of sarcoidosis.

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.CrossRef

Keijsers RG, van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J. 2013;41:743–51.CrossRefPubMed

Cascini GL, Cuccurullo V, Mansi L. The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging. 2010;54:24–36.PubMed

Courtois A, Nusgens BV, Hustinx R, Namur G, Gomez P, Somja J, et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med. 2013;54:1740–7.CrossRefPubMed

Blokhuis GJ, Bleeker-Rovers CP, Diender MG, Oyen WJ, Draaisma JM, de Geus-Oei LF, et al. Diagnostic value of FDG-PET/(CT) in children with fever of unknown origin and unexplained fever during immune suppression. Eur J Nucl Med Mol Imaging. 2014;41:1916–23.CrossRefPubMed

Nakatsuka Y, Handa T, Nakamoto Y, Nobashi T, Yoshihuji H, Tanizawa K, et al. Total lesion glycolysis as an IgG4-related disease activity marker. Mod Rheumatol. 2015;25:579–84.CrossRefPubMed

Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47–59.CrossRefPubMed

Klabatsa A, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski L, Cook GJ, et al. The association of (18)F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2014;41:276–82.CrossRefPubMed

Vera P, Mezzani-Saillard S, Edet-Sanson A, Menard JF, Modzelewski R, Thureau S, et al. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging. 2014;41:1057–65.CrossRefPubMed

10.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122s–50s.CrossRefPubMedPubMedCentral

11.

Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–32.CrossRefPubMed

12.

Braun JJ, Kessler R, Constantinesco A, Imperiale A, et al. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:537–43.CrossRef

13.

Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasculitis Diffuse Lung Dis. 2008;25:143–9.

14.

Dalm VA, van Hagen PM, Krenning EP. The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis. Q J Nucl Med. 2003;47:270–8.PubMed

15.

ten Bokum AM, Hofland LJ, de Jong G, Bouma J, Melief MJ, Kwekkeboom DJ, et al. Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas. Eur J Clin Invest. 1999;29:630–6.CrossRefPubMed

16.

Lebtahi R, Crestani B, Belmatoug N, Daou D, Genin R, Dombret MC, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21–6.PubMed

17.

Piotrowski WJ, Bienkiewicz M, Frieske I, Marczak J, Antczak A, Gorski P, et al. Somatostatin receptor scintigraphy in sarcoidosis: relation to selected clinical and laboratory markers. Pol Arch Med Wewn. 2012;122:98–106.PubMed

18.

Prager E, Wehrschuetz M, Bisail B, Woltsche M, Schwarz T, Lanz H, et al. Comparison of 18F-FDG and 67 Ga-citrate in sarcoidosis imaging. Nuklearmedizin. 2008;47:18–23.PubMed

19.

Tannen BL, Kolomeyer AM, Turbin RE, Frohman L, Langer PD, Oh C, et al. Lacrimal gland uptake of (67)Ga-gallium citrate correlates with biopsy results in patients with suspected sarcoidosis. Ocul Immunol Inflamm. 2014;22:15–22.CrossRefPubMed

20.

Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, et al. Comparative evaluation of 18F-FDG PET and 67 Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571–6.PubMed

21.

Vallabhajosula SR, Harwig JF, Siemsen JK, Wolf W. Radiogallium localization in tumors: blood binding and transport and the role of transferrin. J Nucl Med. 1980;21:650–6.PubMed

22.

Tsan MF. Mechanism of gallium-67 accumulation in inflammatory lesions. J Nucl Med. 1985;26:88–92.PubMed

23.

Ando A, Nitta K, Ando I, Sanada S, Katsuda S, Tonami N, et al. Mechanism of gallium 67 accumulation in inflammatory tissue. Eur J Nucl Med. 1990;17:21–7.CrossRefPubMed

24.

Tsan MF, Chen WY, Scheffel U, Wagner HN Jr. Studies on gallium accumulation in inflammatory lesions: I. Gallium uptake by human polymorphonuclear leukocytes. J Nucl Med. 1978;19:36–43.PubMed

25.

Menon S, Wagner HN Jr, Tsan MF. Studies on gallium accumulation in inflammatory lesions: II. Uptake by Staphylococcus aureus: concise communication. J Nucl Med. 1978;19:44–7.PubMed

26.

Keijsers RG, Verzijlbergen FJ, Oyen WJ, van den Bosch JM, Ruven HJ, van Velzen-Blad H, et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36:1131–7.CrossRefPubMed

27.

Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4:1.CrossRefPubMedPubMedCentral

28.

Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23:244–52.CrossRefPubMed

29.

Reiter T, Werner RA, Bauer WR, Lapa C, et al. Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. Eur Heart J. 2015;36:2404.CrossRefPubMed

30.

Kohn H, Klech H, Mostbeck A, Kummer F. 67 Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood T-lymphocytes. Eur J Nucl Med. 1982;7:413–6.CrossRefPubMed

31.

Beaumont D, Herry JY, Sapene M, Bourguet P, Larzul JJ, de Labarthe B, et al. Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage. Thorax. 1982;37:11–8.CrossRefPubMedPubMedCentral

32.

Lieberman J, Schleissner LA, Nosal A, Sastre A, Mishkin FS, et al. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest. 1983;84:522–8.CrossRefPubMed

33.

Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WA, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998;25:1284–92.CrossRefPubMed

34.

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:48–52.CrossRefPubMed

35.

Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, et al. 68 Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38:1224–36.CrossRefPubMed

36.

Saboury B, Salavati A, Brothers A, Basu S, Kwee TC, Lam MG, et al. FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging. 2014;41:605–14.CrossRefPubMed

Titel: The utility of PET/CT with 68Ga-DOTATOC in sarcoidosis: comparison with 67Ga-scintigraphy
verfasst von: Tomomi Nobashi
Yuji Nakamoto
Takeshi Kubo
Takayoshi Ishimori
Tomohiro Handa
Kiminobu Tanizawa
Kohei Sano
Michiaki Mishima
Kaori Togashi
Publikationsdatum: 07.06.2016
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 8/2016
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-016-1095-6

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

18F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypes

Functional volumetric analysis of striatum using F-18 FP-CIT PET in patients with idiopathic Parkinson’s disease and normal subjects

Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study

Preclinical and first-in-man studies of [11C]CB184 for imaging the 18-kDa translocator protein by positron emission tomography

Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)

Effect of 18F-fluorodeoxyglucose extravasation on time taken for tumoral uptake to reach a plateau: animal and clinical PET analyses